Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Samsung Biologics Co.,Ltd.    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
08/05/2020 08/06/2020 08/07/2020 08/10/2020 08/11/2020 Date
787000 778000 768000 771000 804000 Last
521089 286880 167219 177707 756849 Volume
+7.07% -1.14% -1.29% +0.39% +4.28% Change
Financials
Sales 2019 602 B 0,51 B 0,51 B
Net income 2019 44,8 B 0,04 B 0,04 B
Net cash position 2019 237 B 0,20 B 0,20 B
P/E ratio 2019 1 179x
Yield 2019 0,01%
Sales 2020 1 017 B 0,86 B 0,86 B
Net income 2020 249 B 0,21 B 0,21 B
Net cash position 2020 361 B 0,31 B 0,31 B
P/E ratio 2020 205x
Yield 2020 -
Capitalization 53 197 B 44 827 M 45 004 M
EV / Sales 2019 88 372x
EV / Sales 2020 52 300x
Nbr of Employees 2 534
Free-Float 24,9%
More Financials
Company
SAMSUNG BIOLOGICS CO.,LTD. is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops, manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of Samsung Biologics Co.,Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on SAMSUNG BIOLOGICS CO.,LTD.
07/04Lee Jae-yong admitted in 2016 to have received reports of unfair merger betwe..
AQ
06/26Samsung group heir should not be indicted, South Korea panel recommends
RE
06/11OUTSIDE PANEL TO REVIEW SAMSUNG HEIR : Seoul prosecutors
RE
06/11Outside panel to review Samsung heir Lee's case - Seoul prosecutors
RE
06/09Samsung's Lee Avoids Arrest Warrant -- WSJ
DJ
06/08South Korean court denies arrest warrant request for Samsung heir
RE
06/08South Korean court denies arrest warrant request for Samsung heir
RE
06/08South Korean Court Denies Arrest Warrant for Samsung's Lee Jae-Yong -- Update
DJ
06/08South Korean Court Denies Arrest Warrant for Samsung's Lee Jae-Yong
DJ
06/08Samsung leader appears in court, waits to hear if he'll be jailed again
RE
06/08Samsung leader appears in court, waits to hear if he'll be jailed again
RE
06/04SAMSUNG ELECTRONICS : Prosecutors seek arrest warrant for Samsung chief
AQ
06/04South Korea seeks arrest of Samsung heir Lee in succession probe
RE
05/26Samsung heir questioned over controversial deal
RE
05/26Korean prosecutors question Samsung heir in succession-related probe
RE
More news
News in other languages on SAMSUNG BIOLOGICS CO.,LTD.
07/04Lee Jae-yong admitted in 2016 to have received reports of unfair merger betwe..
06/26Samsung group heir should not be indicted, South Korea panel recommends
06/11OUTSIDE PANEL TO REVIEW SAMSUNG HEIR : Seoul prosecutors
06/11Outside panel to review Samsung heir Lee's case - Seoul prosecutors
06/09Samsung's Lee Avoids Arrest Warrant -- WSJ
More news
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 771 000,00 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Tae-Han Kim Chief Executive Officer & Director
Ho-Yeol Yoon Managing Director & Head-Operations Support
James J. Choi Managing Director & Head-Information Technology
Yong-Ho An Managing Director & Head-Process Technology
Dong-Joong Kim Director & Head-Management Support
Sector and Competitors
1st jan.Capitalization (M$)
SAMSUNG BIOLOGICS CO.,LTD.78.06%42 987
CSL LIMITED1.36%90 829
BIOGEN INC.1.19%47 535
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.222.55%36 815
WUXI BIOLOGICS (CAYMAN) INC.68.68%29 141
UCB45.06%22 881